Clawson, Alicia

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Stein, E. M., Garcia-Manero, G., Rizzieri, D. A., Tibes, R., Berdeja, J. G., Savona, M. R., Jongen-Lavrenic, M., Altman, J. K., Thomson, B., Blakemore, S. J., et al. (2018) · Blood

Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

Cited by 461

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Zauderer, M. G., Szlosarek, P., Le Moulec, S., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Jahan, T., Koczywas, M., Forster, M., et al. (2018) · Journal of Clinical Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 54

A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.

Chi, S. N., McCowage, G. B., Hoffman, L., Macy, M., Doleman, S., Blakemore, S. J., Clawson, A., Daigle, S., Tang, J., Roche, M., et al. (2016) · Journal of Clinical Oncology

Chromatin Remodeling and CancerSarcoma Diagnosis and Treatment

Cited by 8